article thumbnail

How AI will reshape pharma by 2025

Drug Target Review

Looking ahead, 2025 could represent a major turning point for the pharmaceutical sector. In 2025, I think well see breakthroughs that allow us to make significant advances in rare diseases, where the data is small. While current breakthroughs are impressive, Smith anticipates even greater advancements by 2025.

article thumbnail

Keypoint Newsletter: Introducing the New Fellows Class of 2025

keypoint

Meet the Keystone Symposia Fellows Class of 2025, a stellar group of post-doctoral fellows and early-career scientists who will take part in this prestigious mentorship program.

Doctors 122
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The top biopharma conferences in 2025

BioPharma Drive: Drug Pricing

Here’s a list of conferences to watch in 2025. Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies' research progress.

article thumbnail

SAVE THE DATE: Drug Channels Leadership Forum, March 17-19, 2025

Drug Channels

This unique, new event will be held from March 17 to 19, 2025, at the Turnberry Resort and Spa in Miami. I am pleased to announce the inaugural Drug Channels Leadership Forum !

article thumbnail

NEW: The Drug Channels 2025 Video Webinar Series

Drug Channels

Drug Channel Institute is pleased to announce The Drug Channels 2025 Video Webinar Series. Fein for three live video webinars during 2025. Join Dr. Adam J. These live, interactive events will be broadcast via Zoom from the Drug Channels Video studio in beautiful downtown Philadelphia. drug channel. to 1:30 p.m.

Drugs 52
article thumbnail

H1’s Predictions for Healthcare and Pharma in 2025

H1 Blog

In this edition, our CEO and co-founder, Ariel Katz, along with Regional VP of Trial Landscape, Ryan Brown, share their top predictions for 2025. Ryan Brown , Regional VP, Trial Landscape Global standards for diversity plans will emerge in 2025. Ariel Katz , CEO & Co-Founder AI will be used to combat rare diseases.

article thumbnail

Merck targets 2025 RSV season with antibody now under FDA review

BioPharma Drive: Drug Pricing

An FDA approval of Merck’s drug clesrovimab by June would give physicians another option for protecting newborns from respiratory syncytial virus.

FDA 92